The Spectranetics Corporation (NASDAQ:SPNC)

The Spectranetics Corporation, together with its subsidiaries, develops, manufactures, markets, and distributes single-use medical devices used in minimally invasive procedures in the cardiovascular system. Its products are used to treat arterial blockages in the heart and legs, and to remove pacemaker and defibrillator cardiac leads. The company's vascular intervention product line includes peripheral atherectomy, coronary atherectomy, crossing solutions, thrombus management, and therapeutic infusion system. Its peripheral atherectomy product line consists of a selection of proprietary laser catheters for the treatment of infrainguinal (leg) arterial stenoses and occlusions; coronary atherectomy product line comprises proprietary laser catheters that are used in various coronary artery diseases; and crossing solutions catheter products support guidewires and other devices in facilitating vascular access in the arterial system to enable various interventions. The Spectranetics Corporation’s thrombus management product line consists of thrombus removal devices intended to remove fresh, soft thrombi, and emboli from vessels in the arterial system, as well as to address thrombotic occlusions in dialysis grafts and fistulae; and therapeutic infusion catheter enables targeted local delivery of physician-specified drug or diagnostic agent for the treatment of long vessels and multiple blockages with one device. Its lead management product line comprises Spectranetics Laser Sheath, GlideLight, Lead Locking Device, and VisiSheath Dilator Sheath for the removal of pacemaker and defibrillator cardiac leads. The company sells its products in the United States, Canada, Europe, the Middle East, the Asia Pacific, Latin America, and Puerto Rico. The Spectranetics Corporation was founded in 1984 and is headquartered in Colorado Springs, Colorado.